Jon E. Angell

Array ( [id] => 11277364 [patent_doc_number] => 09493841 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-15 [patent_title] => 'Treatment of angiogenesis disorders' [patent_app_type] => utility [patent_app_number] => 14/658927 [patent_app_country] => US [patent_app_date] => 2015-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 65 [patent_no_of_words] => 24240 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 145 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14658927 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10355237 [patent_doc_number] => 20150240242 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-27 [patent_title] => 'Compositions And Methods For Inhibiting Expression Of IKK-B Gene' [patent_app_type] => utility [patent_app_number] => 14/637136 [patent_app_country] => US [patent_app_date] => 2015-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 27579 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14637136 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10361064 [patent_doc_number] => 20150246069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-03 [patent_title] => 'METHOD OF USING SEQUENCE OF ANTAGOMIR FOR DEVELOPING MEDICINE FOR INHIBITING ORAL CANCER CELLS FROM SPREADING' [patent_app_type] => utility [patent_app_number] => 14/621824 [patent_app_country] => US [patent_app_date] => 2015-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 4226 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14621824 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14665647 [patent_doc_number] => 10370716 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-06 [patent_title] => Methods of diagnosing and treating medullary cystic kidney disease [patent_app_type] => utility [patent_app_number] => 14/618525 [patent_app_country] => US [patent_app_date] => 2015-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 14317 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14618525 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10306743 [patent_doc_number] => 20150191745 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-09 [patent_title] => 'LENTIVIRAL TRIPLEX DNA, AND VECTORS AND RECOMBINANT CELLS CONTAINING LENTIVIRAL TRIPLEX DNA' [patent_app_type] => utility [patent_app_number] => 14/613657 [patent_app_country] => US [patent_app_date] => 2015-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 17530 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14613657 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11289121 [patent_doc_number] => 20160339053 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-24 [patent_title] => 'Compositions and Methods for Treating Autoimmune and Inflammatory Diseases' [patent_app_type] => utility [patent_app_number] => 15/114572 [patent_app_country] => US [patent_app_date] => 2015-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 16630 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15114572 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12092803 [patent_doc_number] => 20170349896 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-07 [patent_title] => 'POLY OLIGOMER COMPOUND WITH BIOCLEAVABLE CONJUGATES' [patent_app_type] => utility [patent_app_number] => 15/114274 [patent_app_country] => US [patent_app_date] => 2015-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 62841 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15114274 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12044766 [patent_doc_number] => 09822359 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2017-11-21 [patent_title] => 'Method of treating neurological disorders using long non-coding RNAs' [patent_app_type] => utility [patent_app_number] => 14/602945 [patent_app_country] => US [patent_app_date] => 2015-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 13 [patent_no_of_words] => 18073 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14602945 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11205327 [patent_doc_number] => 09434947 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-09-06 [patent_title] => 'Modulation of KCNH2 isoform expression by oligonucleotides as a therapeutic approach for long QT syndrome' [patent_app_type] => utility [patent_app_number] => 14/600958 [patent_app_country] => US [patent_app_date] => 2015-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 18 [patent_no_of_words] => 9844 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14600958 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11815144 [patent_doc_number] => 09719087 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-01 [patent_title] => 'Micro-RNA family that modulates fibrosis and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/592699 [patent_app_country] => US [patent_app_date] => 2015-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 28 [patent_no_of_words] => 30917 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14592699 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11815143 [patent_doc_number] => 09719086 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-01 [patent_title] => 'Micro-RNA family that modulates fibrosis and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/592686 [patent_app_country] => US [patent_app_date] => 2015-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 28 [patent_no_of_words] => 30912 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14592686 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11815145 [patent_doc_number] => 09719088 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-01 [patent_title] => 'Micro-RNA family that modulates fibrosis and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/592737 [patent_app_country] => US [patent_app_date] => 2015-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 28 [patent_no_of_words] => 30919 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14592737 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12347619 [patent_doc_number] => 09951376 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-24 [patent_title] => Methods for the selection of aptamers [patent_app_type] => utility [patent_app_number] => 14/590634 [patent_app_country] => US [patent_app_date] => 2015-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 8 [patent_no_of_words] => 9825 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 317 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14590634 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11915630 [patent_doc_number] => 09783808 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-10 [patent_title] => 'Ovarian cancer-specific aptamers and applications thereof' [patent_app_type] => utility [patent_app_number] => 14/558659 [patent_app_country] => US [patent_app_date] => 2014-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 21 [patent_no_of_words] => 6687 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 183 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14558659 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11212192 [patent_doc_number] => 09441221 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-09-13 [patent_title] => 'Compositions and methods for gene silencing' [patent_app_type] => utility [patent_app_number] => 14/529923 [patent_app_country] => US [patent_app_date] => 2014-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 59 [patent_figures_cnt] => 97 [patent_no_of_words] => 39304 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14529923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10318868 [patent_doc_number] => 20150203870 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-23 [patent_title] => 'METHODS AND COMPOSITIONS RELATING TO IMPROVED LENTIVIRAL VECTOR PRODUCTION SYSTEMS' [patent_app_type] => utility [patent_app_number] => 14/525520 [patent_app_country] => US [patent_app_date] => 2014-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 25095 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14525520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9895148 [patent_doc_number] => 20150050347 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-19 [patent_title] => 'REVERSE MICELLE SYSTEM COMPRISING NUCLEIC ACIDS AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/520399 [patent_app_country] => US [patent_app_date] => 2014-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 12428 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14520399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15883307 [patent_doc_number] => 10647986 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-12 [patent_title] => Dynamin 2 inhibitor for the treatment of centronuclear myopathies [patent_app_type] => utility [patent_app_number] => 15/030127 [patent_app_country] => US [patent_app_date] => 2014-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 30 [patent_no_of_words] => 15933 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15030127 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11054697 [patent_doc_number] => 20160251660 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-01 [patent_title] => 'NUCLEIC ACID APTAMER CAPABLE OF SPECIFICALLY BINDING TO TEBUCONAZOLE, MEFENACET AND INABENFIDE, AND USE THEROF' [patent_app_type] => utility [patent_app_number] => 15/028931 [patent_app_country] => US [patent_app_date] => 2014-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 6615 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15028931 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13237431 [patent_doc_number] => 10131907 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-11-20 [patent_title] => Glycoconjugates of RNA interference agents [patent_app_type] => utility [patent_app_number] => 14/500356 [patent_app_country] => US [patent_app_date] => 2014-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 20532 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14500356 [rel_patent_id] =>[rel_patent_doc_number] =>)